The report quotes Dr. Brian Cox, MB ChB, PhD, the director of the Hugh Adam cancer epidemiology unit at Otago University, as saying, “It’s becoming very, very clear that prostate cancer screening doesn’t appear to work.” On other web sites in New Zealand, such as the Otago Daily Times , Dr. Cox is reported to have “appealed to the Ministry of Health and Cancer Control … to take appropriate actions to stop testing men without the symptoms of the disease.”
The “New” Prostate Cancer InfoLink has consistently held a position that mass, population-based “screening” of all men for prostate cancer (particularly on an annual basis) is not justified by any available data. However, the idea that we should “stop testing men without the symptoms of the disease” is certifiably insane. This would return men to a time in the late 1980s when the majority of men diagnosed with prostate cancer had progressive disease at the time of diagnosis.
It is true, in our opinion, that expectations of PSA testing are overblown, and can and do result in many men with indolent prostate cancer receiving unneeded treatment. We desperately need to do a much better job of appropriate use of the PSA test among those men at the highest levels of risk for progressive forms of prostate cancer while simultaneously educating the male population about the risks associated with over-treatment and the values of active surveillance. However, if we throw the baby out with the bath water as Dr. Cox is suggesting we will be committing a significant group of men with curable forms of aggressive but localized prostate cancer to metastatic disease and (potentially) prostate cancer-specific mortality.
We agree with Dr. Cox that we need better tests than the PSA test … and we need such tests soon … but that is no reason to cast men at risk for prostate cancer into the outer darkness until such a test is available. In the meantime we need to be doing the best possible job with the tools that we have available and the PSA tests is very certainly one of those tools.
New Zealand does not have a formally approved prostate cancer screening initiative; the PSA test is used by men in New Zealand (and their doctors) to assess their individual risk for prostate cancer (presumably based on the normal factors like race, family history, etc.). We would suggest to Dr. Cox that he use his stature to help to educate men in New Zealand (and their primary care physicians) when and how to use the PSA test appropriately, as opposed to just calling the media to set back male health care by 30 years! He clearly did not read at least one of the statements attributed to the lead author of the Norrkoping study.
Although Dr. Sandblom did indeed state that the results of the Norrkoping trial could not justify the use of mass, population-based prostate cancer screening, he also said, based on the structure and results of that trial, that: “I would thus not categorically advise against PSA testing based on an individual decision from a man who feels concern about prostate cancer.” [Bold italic type added for emphasis.] There is a sound middle ground available for those among us who don’t think that every man over 40 needs a PSA test every year and it is not the simple opposite.